Combination tumor ‐treating fields treatment for patients with metastatic non‐small cell lung cancer: A cost‐effectiveness analysis

ConclusionsIn the United States, TTFields plus SOC as second-line treatment was not a more cost-effective strategy for patients with mNSCLC. Of the analyzed regimens, TTFields plus ICI was associated with most significant health benefits.

Source: Cancer Medicine - March 12, 2024 Category: Cancer & Oncology Authors: Kun Liu, Youwen Zhu, Hong Zhu, Manting Zeng Tags: RESEARCH ARTICLE Source Type: research